Shots:

• The P-III trial involves assessing REGEN-COV (casirivimab & imdevimab- 1200/2400mg- IV) vs PBO in non-hospitalized patients with COVID-19
• The trial met its 1EPs i.e. showed a reduction in the risk of hospitalization and death with both doses by 70% /71% respectively and met its 2EPs including the ability to reduce symptom duration. The P-II trial showed viral reductions for all REGEN-COV doses tested- including as low as 300 mg
• Additionally- Regeneron will share new data with regulatory authorities immediately and request that a lower 1-200 mg dose be added to EUA

 ­ Ref: Regeneron | Image: WRGB